Statins: in the beginning.
Since the first human trial of a hydroxymethylglutaryl-coenzyme A (HMG CoA) reductase inhibitor in 1978, the growth in importance of this drug class, both financially and medically, has been staggering. The aim of this paper is to summarise how this drug class was developed, highlighting the role ofAkira Endo.
Department of Therapeutics and Pharmacology, Queen's University, Belfast. klyons01@qub.ac.uk
K S
KS
Lyons
M
M
Harbinson
D000924:Anticholesteremic Agents / Q000266:history*; D049673:History, 20th Century; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000266:history* / Q000627:therapeutic use; D007564:Japan; D008148:Lovastatin / Q000031:analogs & derivatives / Q000266:history
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; C012258:mevastatin; D008148:Lovastatin